10-Q quarterly report · filed Nov 5, 2026

PALVELLA THERAPEUTICS, INC. (PVLA) Q3 2026 10-Q Quarterly Report

Short answer

PALVELLA THERAPEUTICS, INC. (PVLA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$25M
−117.2% YoY · −12.7% QoQ
EPS (diluted)
−$1.71
−66.0% YoY · −11.0% QoQ

Source: XBRL data from the PALVELLA THERAPEUTICS, INC. (PVLA) Q3 2026 10-Q on SEC EDGAR. USD.

PALVELLA THERAPEUTICS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • No product revenue, consistent with no commercial revenue or operating cash flows expected near-term
  • Net loss $24.6M vs $11.3M YoY, operating loss $22.7M vs $10.2M
  • R&D expense $10.8M vs $6.5M YoY, G&A expense $11.9M vs $3.6M
  • Cash and short-term investments $236.7M, operating cash outflow $38.1M, financing inflow $216.5M
  • FDA Priority Review, PDUFA date February 28, 2027, planned U.S. launch first half of 2027 if approved

Risk Factors

  • No material changes reported from the 2025 Form 10-K
  • Financing risk: securities investment involves a high degree of risk
  • Disclosure risk: quarterly results require review alongside MD&A and unaudited financial statements
  • Carried-forward risks: 2025 Form 10-K risk factors remain applicable

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other PALVELLA THERAPEUTICS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.